NY

Naveen Yalamanchi

Partner at RTW Investments, LP

New York, New York

Invests in

Stages:

  • Min Investment:

    $10,000,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Partner

    2015

    Portfolio manager at RTW - $6.5b AUM healthcare investment firm. www.RTWfunds.com

  • Dean's Leadership Council

    2025

  • Board Observer

    2019

  • Board Observer

    2018

  • Co-Founder and Board Director

    2015 - 2025

    A clinical stage gene therapy company. Lead indications include: Danon Disease, Fanconi Anemia, Pyruvate Kinase Deficiency. (NASDAQ: RCKT) www.rocketpharma.com

2023 - 2024

  • Board Observer

    2023 - 2024

  • Chief Financial Officer

    2020 - 2023

    Health Sciences Acquisitions Corporation 2 (NASDAQ: HSAQ) completed a business combination with Orchestra Biomed (NASDAQ:OBIO) in Jan 2023.

  • Chief Financial Officer

    2019 - 2019

    Health Sciences Acquisitions Corporation (NASDAQ: HSAC) merged with Immunovant Ltd on December 18, 2019. The combined entity is "Immunovant, Inc" (NASDAQ: IMVT).

2017 - 2019

  • Board Observer

    2017 - 2019